_____________________________________________________________________________________________________________ Hikma
By proactively monitoring potential supply disruptions and collaborating with partners, we can anticipate shortages, scale production when needed, and maintain continuity of care in a volatile market
which accelerate our progress through targeted acquisition. Our Tyzavan ® launch exemplifies this strategy; our R & D team in Zagreb developed this ready-to-use formulation with room temperature stability. This achievement demonstrates our ability to integrate acquired knowledge with internal expertise to deliver innovative solutions. By focusing on complex injectables, we’ re expanding our portfolio while reinforcing our position as a trusted partner for advanced therapies.”
Looking ahead, Hikma will continue to expand its Injectables division by increasing its manufacturing footprint across North America, Europe, and the MENA region, with a view to strengthen its supply chain, reduce lead times, mitigate logistic risks, and ensure uninterrupted access to critical medicine.“ This regionalized model enhances resilience and positions us closer to patients and healthcare providers,” Natheer concludes.“ This reinforces Hikma’ s competitive advantage, allowing us to respond faster to market needs, support global health priorities and deliver sustainable growth.” ■
www. hikma. com
manufacturing-today. com 47